Everlywell rolls out Clairity AI for breast cancer in US
Digital health provider Everlywell is launching an AI that can assess the risk of developing breast cancer from a routine mammogram, developed by medtech firm Clairity, across its US network.
Austin, Texas-based Everlywell said the move – which coincides with Breast Cancer Awareness Month in the US – will increase access to Clairity Breast, which was the first AI to be authorised by the FDA that can assess a woman's five-year risk of developing the disease from a routine mammography screening.
The partnership also brings together two female-founded, female-led companies, namely Clairity's Dr Connie Lehman and Everlywell's Julia Cheek.
Each year, more than 2.3 million women worldwide are diagnosed with breast cancer, including over 370,000 in the US alone. Many women are still diagnosed after the disease has already progressed, particularly if they have no family history or known risk factors, and Clairity Breast aims to address that issue.
About 85% of breast cancers occur in women with no family history of the disease at all, according to Everlywell, which provides at-home lab testing kits, telehealth virtual care, and personalised wellness tracking, as well as in-person testing services.
Approved in 2025, the AI-powered predictive imaging model detects subtle patterns in breast tissue during a standard 2D mammogram that can indicate future cancer risk, even if the image appears normal to the human eye. Until now, Clairity Breast has had limited availability through health systems, including Beth Israel Deaconess Medical Centre in Massachusetts and Invision Sally Jobe in Colorado.
"The information we need to understand a woman's breast cancer risk has been in her mammogram all along – we just haven't been able to interpret it until Clairity Breast," said Lehman, who is also Professor of Radiology at Harvard Medical School. "Now, it can also inform conversations with your healthcare provider about the best screening and risk reduction options for you."
The partnership is particularly timely, as earlier this year, updated National Comprehensive Cancer Network (NCCN) guidelines introduced AI-based mammogram risk assessment as an option for identifying women at increased risk, beginning at age 35.
Patients with a qualifying recent screening mammogram from the past 12 months will now be able to access the AI tool through the Everlywell platform, according to the two companies.
"This partnership expands access to cutting-edge preventive care, and that means a woman can learn more about her future breast cancer risk from the mammogram she already gets, and walk into her doctor's office with information she's never had before," said Cheek.
Photo by National Cancer Institute on Unsplash
